针对 SARS-CoV-2 的信使 RNA 疫苗。
Messenger RNA vaccines against SARS-CoV-2.
机构信息
Scripps Research, La Jolla, CA, USA.
出版信息
Cell. 2021 Mar 18;184(6):1401. doi: 10.1016/j.cell.2020.12.039. Epub 2021 Jan 13.
Abstract
The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3-4 weeks apart. To view this Bench to Bedside, open or download the PDF.
摘要
前两种经证实可有效抑制 COVID-19 疾病的疫苗均为 mRNA 疫苗，在对 74000 名参与者（一半接受安慰剂）进行肌肉内两剂、间隔 3-4 周的接种后，其有效性（和安全性）达到 95%。要查看本从临床前到临床的转化研究，可打开或下载 PDF。
相似文献
1
Messenger RNA vaccines against SARS-CoV-2.针对 SARS-CoV-2 的信使 RNA 疫苗。
Cell. 2021 Mar 18;184(6):1401. doi: 10.1016/j.cell.2020.12.039. Epub 2021 Jan 13.
2
Could mixing COVID vaccines boost immune response?混合接种新冠疫苗能增强免疫反应吗？
Nature. 2021 Feb;590(7846):375-376. doi: 10.1038/d41586-021-00315-5.
3
[Vaccination immunology in SARS-CoV-2].[新型冠状病毒肺炎中的疫苗接种免疫学]
Ugeskr Laeger. 2021 Mar 15;183(11).
4
The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.mRNA疫苗的世纪：新冠疫苗与过敏
J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):89-91. doi: 10.18176/jiaci.0665. Epub 2020 Jan 4.
5
Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗（BNT126b2）在维持性血液透析患者中的细胞免疫原性和体液免疫原性。
EBioMedicine. 2021 Sep;71:103567. doi: 10.1016/j.ebiom.2021.103567. Epub 2021 Aug 26.
6
A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.一剂重组 VSV-∆G 棘突蛋白疫苗可提供针对 SARS-CoV-2 挑战的保护。
Nat Commun. 2020 Dec 16;11(1):6402. doi: 10.1038/s41467-020-20228-7.
7
Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.基于合成信使 RNA 的疫苗：从不屑一顾到大肆炒作。
Viruses. 2021 Feb 9;13(2):270. doi: 10.3390/v13020270.
8
Coronavirus Disease 2019 Vaccine Development: An Overview.新型冠状病毒肺炎 2019 疫苗研发：概述。
Viral Immunol. 2021 Apr;34(3):134-144. doi: 10.1089/vim.2020.0119. Epub 2020 Sep 23.
9
Neutralizing SARS-CoV-2.中和 SARS-CoV-2
Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.
10
Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.冠状病毒病（COVID-19）：药物和疫苗研发的现状和前景。
Arch Med Res. 2021 Jan;52(1):15-24. doi: 10.1016/j.arcmed.2020.09.010. Epub 2020 Sep 10.
引用本文的文献
1
Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered.流感5xM2e mRNA脂质纳米颗粒疫苗具有广泛的免疫性，当与灭活裂解疫苗共同接种时，能显著提高其效力。
J Immunol. 2025 Jan 1;214(1):104-114. doi: 10.1093/jimmun/vkae013.
2
Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus.针对 2.3.4.4b 谱系 H5 高致病性禽流感病毒的核苷修饰 mRNA 疫苗的研制。
Nat Commun. 2024 May 23;15(1):4350. doi: 10.1038/s41467-024-48555-z.
3
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.表面修饰的麻疹疫苗编码三聚体、预融合稳定的 SARS-CoV-2 刺突糖蛋白，可增强对奥密克戎和历史变异株的中和抗体应答，与麻疹血清阳性无关。
mBio. 2024 Feb 14;15(2):e0292823. doi: 10.1128/mbio.02928-23. Epub 2024 Jan 9.
4
Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSV) in golden syrian hamster.基于高度减毒水泡性口炎病毒载体（VSV）的黏膜型新冠疫苗候选物在金黄地鼠中的免疫原性。
Acta Pharm Sin B. 2023 Dec;13(12):4856-4874. doi: 10.1016/j.apsb.2023.08.023. Epub 2023 Aug 25.
5
Nanoparticles: a breakthrough in COVID-19 prevention, diagnosis and treatment.纳米颗粒：新冠病毒预防、诊断与治疗的一项突破。
Arch Med Sci. 2021 Oct 15;19(5):1410-1420. doi: 10.5114/aoms/142103. eCollection 2023.
6
Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes.住院 2 型糖尿病患者对灭活 COVID-19 疫苗的抗体反应受损。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2184754. doi: 10.1080/21645515.2023.2184754. Epub 2023 Mar 2.
7
Research progress on circular RNA vaccines.环状 RNA 疫苗的研究进展。
Front Immunol. 2023 Jan 12;13:1091797. doi: 10.3389/fimmu.2022.1091797. eCollection 2022.
8
COVID-19 vaccines and a perspective on Africa.COVID-19 疫苗和非洲视角。
Trends Immunol. 2023 Mar;44(3):172-187. doi: 10.1016/j.it.2023.01.005. Epub 2023 Jan 11.
9
A Thermal and Enzymatic Dual-Stimuli Responsive DNA-Based Nanomachine for Controlled mRNA Delivery.一种用于控制 mRNA 递送的热-酶双响应性 DNA 纳米机器。
Adv Sci (Weinh). 2023 Feb;10(4):e2204905. doi: 10.1002/advs.202204905. Epub 2022 Dec 3.
10
High throughput bioluminescent assay to characterize and monitor the activity of SARS-CoV-2 methyltransferases.高通量生物发光分析方法用于鉴定和监测 SARS-CoV-2 甲基转移酶的活性。
PLoS One. 2022 Nov 29;17(11):e0274343. doi: 10.1371/journal.pone.0274343. eCollection 2022.
本文引用的文献
1
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
2
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.mRNA 疫苗对 SARS-CoV-2 的作用-初步报告。
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.
Zotero 插件